Evidence map›Paper›PMID 39616161›Full record

ArticleCell death & disease2024

A N7-methylguanosine modified circular RNA, circIPP2A2, promotes malignant behaviors in hepatocellular carcinoma by serving as a scaffold in modulating the Hornerin/PI3K/AKT/GSK3β axis.

Zeyi Guo, Zhongzhe Li, Jinhao Guo, Luxiang Gan, Haiyu Mo, Jiajun Zhang, Yu Fu, Yi Wang, Meixian Jin, Yanping Wu and 9 more

Abstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Zeyi Guo *Department of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, 510000, Guangzhou, Guangdong, P. R. China.
Zhongzhe Li *Department of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, 510000, Guangzhou, Guangdong, P. R. China.
Jinhao Guo *Department of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, 510000, Guangzhou, Guangdong, P. R. China.
Luxiang Gan *Department of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, 510000, Guangzhou, Guangdong, P. R. China.
Haiyu MoDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 510000, Guangzhou, P. R. China.
Jiajun ZhangDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, 510000, Guangzhou, Guangdong, P. R. China.
Yu FuDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, 510000, Guangzhou, Guangdong, P. R. China.
Yi WangShanxi Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, 030013, Taiyuan, P. R. China.
Meixian JinDepartment of Anesthesiology of the Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, 518172, Shenzhen, P. R. China.
Yanping WuDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, 510000, Guangzhou, Guangdong, P. R. China.
Qingyu XieDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, 510000, Guangzhou, Guangdong, P. R. China.
Kunjiang TanThe Eastern Hepatobiliary Surgery Hospital, Naval Medical University, 200000, Shanghai, P. R. China.
Chunming WangDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, 510000, Guangzhou, Guangdong, P. R. China.
Yuyan XuDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, 510000, Guangzhou, Guangdong, P. R. China.
Guolin HeDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, 510000, Guangzhou, Guangdong, P. R. China.
Lei CaiDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, 510000, Guangzhou, Guangdong, P. R. China.
Yi GaoDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, 510000, Guangzhou, Guangdong, P. R. China. gaoyi@smu.edu.cn.
Mingxin PanDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, 510000, Guangzhou, Guangdong, P. R. China. pmxwxy@sohu.com.
Shunjun FuDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, 510000, Guangzhou, Guangdong, P. R. China. fsj103@163.com.ORCID 0000-0001-5318-5908

Funding

Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation) 2021B1515230011Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation) 2023A1515010141Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation) 2024A1515012205
6 · The paper itself

Abstract

Despite the advancements in treatment strategies, the long-term survival of hepatocellular carcinoma (HCC) is still pessimistic. Therefore, understanding the mechanisms of hepatocellular carcinoma may offer substantial benefits for patients. Our previous research has revealed that Hornerin promoted HCC progression by regulating the AKT signaling pathway. To investigate the upstream regulatory mechanism, the results from RNA Immunoprecipitation and RNA pull-down indicated that the specific region of circIPP2A2 interacted with Hornerin. Additionally, patients with circIPP2A2 upregulation exhibited a poorer survival outcome following surgery compared to the cases with downregulated circIPP2A2. After the structure verification of circIPP2A2, loss-of-function studies using a lentiviral vector revealed that circIPP2A2 downregulation significantly inhibited HCC tumorigenesis and progression both in vitro and in vivo. Mechanistically, the m7G-MeRIP results demonstrated significant enrichment of circIPP2A2. Subsequent studies validated that METTL1 influenced the stability of circIPP2A2 and its binding affinity with Hornerin. Immunoprecipitation and immunofluorescence indicated that circIPP2A2 served as a molecular scaffold to facilitate Hornerin to interact with PI3K. In conclusion, our findings reveal that circIPP2A2, regulated by N7-methylguanosine modification, promotes malignant behaviors in HCC by serving as a molecular scaffold in modulating the Hornerin/PI3K/AKT/GSK3β axis. Targeting circIPP2A2 may be a promising therapeutic strategy for patients with HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMethyltransferasesRNA, CircularS100 ProteinsAnimalsCalcium-Binding ProteinsCell Line, TumorGene Expression Regulation, NeoplasticGlycogen Synthase Kinase 3 betaGuanosineHep G2 CellsHumansIntermediate Filament ProteinsMicePhosphatidylinositol 3-Kinases1-methylguanosineCalcium-Binding ProteinsGlycogen Synthase Kinase 3 betaGuanosineHRNR protein, humanIntermediate Filament ProteinsMethyltransferasesMETTL1 protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, CircularS100 Proteins

Identifiers

PMID39616161
PMCPMC11608253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.